An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers

PARP inhibitors yield interesting outcomes for patients with ovarian tumors harboring <i>BRCA1</i> or <i>BRCA2</i> mutation, but also with other tumors with homologous repair (HR) deficiency. About 40% of variants are variants of unknown significance (VUS), blocking the use o...

Full description

Bibliographic Details
Main Authors: Sandy Chevrier, Corentin Richard, Thomas Collot, Hugo Mananet, Laurent Arnould, Romain Boidot
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
VUS
homologous recombination
PARP inhibitors
response
progression-free survival
Online Access:https://www.mdpi.com/2072-6694/13/13/3113

Internet

https://www.mdpi.com/2072-6694/13/13/3113

Similar Items